Get the facts on diseases, conditions, tests and procedures.
Enter the last name, specialty or keyword for your search below.
Research Interests: Cell-based therapeutics and the tumor microenvironment.
Levy O, Brennen WN, Han E, Rosen DM, Musabeyezu J, Safaee H, Ranganath S, Ngai J, Heinelt M, Milton Y, Wang H, Bhagchandani SH, Joshi N, Bhowmick N, Denmeade SR, Isaacs JT, Karp JM. A prodrug-doped cellular Trojan Horse for the potential treatment of prostate cancer. Biomaterials. 2016 Jun; 91: 140-50. PMID: 27019026.
Brennen WN, Rosen DM, John T. Isaacs, Denmeade SR. Targeting carcinoma associated fibroblasts within the reactive stroma with a fibroblast activation protein (FAP)-activated prodrug. JNCI. 2012, Sept 5; 104(17): 1320-34. PMID: 22911669.
Brennen WN, Chen S, Denmeade SR, Isaacs JT. Quantification of Mesenchymal Stem Cells (MSCs) at sites of human prostate cancer. Oncotarget. 2013 Jan; 4(1): 106-17. PMID: 23362217.
Brennen WN, Drake CG, Isaacs JT. Enhancement of the T-cell Armamentarium as a Cell-based Therapy for Prostate Cancer. Cancer Res. 2014 Jul 1; 74(13): 3390-5. PMID: 24747912.
Brennen WN, Denmeade SR, Isaacs JT. Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment. Endocr Relat Cancer. 2013 Aug 23; 20(5): R269-90. PMID: 23975882.
Language Assistance Available:
© The Johns Hopkins University, The Johns Hopkins Hospital, and Johns Hopkins Health System. All rights reserved.
